Corporate ActionAug 7, 2026, 04:07 PM
Braveheart Bio Closes Upsized IPO, Raises $439.9M Gross
AI Summary
Braveheart Bio, Inc. announced the closing of its upsized initial public offering, which included the full exercise of the underwriters' option to purchase additional shares. The company sold an aggregate of 24,437,500 shares of its common stock at an IPO price of $18.00 per share, generating gross proceeds of $439.9 million. The shares commenced trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol "BRVE".
Key Highlights
- Braveheart Bio closed its upsized initial public offering (IPO).
- The IPO involved an aggregate of 24,437,500 shares of common stock.
- The initial public offering price was $18.00 per share.
- Underwriters fully exercised their option to purchase 3,187,500 additional shares.
- Gross proceeds from the IPO totaled $439.9 million.
- Shares began trading on the Nasdaq Global Market on August 6, 2026, under ticker "BRVE".
Price Impact
More from BRVE